1David Geffen School of Medicine, UCLA, Los Angeles, CA;
2Department of Obstetrics and Gynecology, Boston Medical Center/Boston University School of Medicine, Boston, MA;
3National HPV Vaccination Program Register, VCS Registries and Research, Victorian Cytology Service, East Melbourne, Victoria, Australia;
4Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia;
5VCS Pathology, Carlton, Victoria, Australia; and
6Department of Obstetrics and Gynaecology, University of Melbourne, Victoria, Australia
Reprint requests to: Rebecca B. Perkins, MD, 85 E. Concord St 6th Floor, Department of Obstetrics and Gynecology, Boston University School of Medicine/Boston Medical Center, Boston MA 02118. E-mail: firstname.lastname@example.org
The institution of J.M.L.B. and M.S. has received research funding for laboratory testing from Roche for the Compass trial and from Seqirus for a cervical cancer typing study. J.M.L.B. was an investigator on an investigator-initiated grant from Merck that supported laboratory testing for a national recurrent respiratory papillomatosis surveillance study. J.M.L.B. and M.S. have never received any personal financial benefits. A.B.M. serves on advisory boards for Merck and Glaxo-Smith-Kline for work unrelated to this article. R.B.P. has declared she has no conflicts of interest.